Holen Sie sich die Stockscreener-App
16.64
0.83%
-0.14
Schlusskurs vom Vortag:
$16.78
Offen:
$16.8
24-Stunden-Volumen:
484.07K
Relative Volume:
0.64
Marktkapitalisierung:
$779.08M
Einnahmen:
$681.75M
Nettoeinkommen (Verlust:
$70.47M
KGV:
184.89
EPS:
0.09
Netto-Cashflow:
$173.19M
1W Leistung:
-2.29%
1M Leistung:
-1.13%
6M Leistung:
-43.95%
1J Leistung:
-36.78%
1-Tages-Spanne:
$16.53
$17.00
1-Wochen-Bereich:
$16.29
$18.09
52-Wochen-Spanne:
$11.16
$35.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
813-553-6680
Adresse
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
Vergleichen Sie PCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
16.64 | 779.08M | 681.75M | 70.47M | 173.19M | 0.09 |
|
ZTS
Zoetis Inc
|
176.74 | 80.59B | 9.15B | 2.43B | 2.31B | 4.92 |
|
HLN
Haleon Plc Adr
|
9.72 | 44.17B | 14.26B | 1.55B | 0 | 0.3327 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.57 | 42.61B | 30.27B | 1.93B | 3.45B | 0.444 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.57 | 18.77B | 16.77B | -959.00M | 1.37B | -2.00 |
|
VTRS
Viatris Inc
|
13.22 | 15.73B | 15.05B | -883.30M | 1.89B | 1.53 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Connor Clark & Lunn Investment Management Ltd. Takes $1.21 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses (NASDAQ:PCRX) - Seeking Alpha
Segall Bryant & Hamill LLC Takes Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Victory Capital Management Inc. Boosts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRX (Pacira BioSciences) Market Cap : $810.3 Mil (As of Nov. 25, 2024) - GuruFocus.com
(PCRX) On The My Stocks Page - Stock Traders Daily
Pacer Advisors Inc. Purchases 2,799,434 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Global Alpha Capital Management Ltd. Sells 49,560 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Empowered Funds LLC Takes $3.29 Million Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - MSN
Janney Montgomery Scott LLC Acquires New Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Impax Asset Management Group plc Boosts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Pacira Announces 104-Week Safety and Efficacy Data - GlobeNewswire
When (PCRX) Moves Investors should Listen - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com Canada
Pacira BioSciences Inc (PCRX) Stock Price Down 3.31% on Nov 12 - GuruFocus.com
Barclays Issues Pessimistic Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira BioSciences to Present at Jefferies and Piper Sandler Healthcare Conferences | PCRX Stock News - StockTitan
Robeco Institutional Asset Management B.V. Invests $1.05 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences Inc (PCRX) Worth Considering For The Next Few Weeks - Stocks Register
Pacira BioSciences' (PCRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $24.20 - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
This Pacira BioSciences Insider Reduced Their Stake By 85% - Simply Wall St
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - MarketBeat
Pacira Pharmaceuticals stock target increased post Q3 earnings report By Investing.com - Investing.com UK
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments - TipRanks
Pacira BioSciences Inc (PCRX) Reports Q3 2024 Revenue of $168.6M, EPS Misses Estimates with $3.11 Loss - GuruFocus.com
Pacira BioSciences Reports Third Quarter 2024 Financial Results - The Manila Times
Pacira BioSciences Reports $168.6M Revenue, Hit by $163.2M Impairment Charge in Q3 | PCRX Stock News - StockTitan
Impax Asset Management Group plc Has $7.08 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Insights into Pacira BioSciences's Upcoming Earnings - Benzinga
Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $24.20 Consensus Target Price from Analysts - MarketBeat
Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings - GlobeNewswire
Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily
Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):